Tag: CytoDyn

The U.S. Securities and Exchange Commission charged Nader Pourhassan, the former CEO of CytoDyn Inc., with fraud and insider trading for misleading shareholders about the progress of a clinical research treatment for COVID-19 and HIV. According to the SEC complaint, Pourhassan repeatedly issued press releases exaggerating CytoDyn’s progress on leronlimab, an…